An Open-label, Multi-centre Study to Evaluate the Long-term Safety and Tolerability of REN001 in Subjects With Primary Mitochondrial Myopathy (PMM)
Latest Information Update: 30 May 2024
Price :
$35 *
At a glance
- Drugs Mavodelpar (Primary)
- Indications Mitochondrial myopathies
- Focus Adverse reactions; Registrational
- Acronyms STRIDE AHEAD
- Sponsors Reneo Pharmaceuticals
- 07 Feb 2024 Status changed from recruiting to discontinued.
- 12 Jan 2024 This trial has been discontinued in Denmark (Global end date: 14 Dec 2023).
- 10 Jan 2024 This trial has been discontinued in Hungary (Global end date: 14 Dec 2023).